Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Active not recruiting 4Completed 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 4

Interventions

pembrolizumab 84Specimen Handling 79Carboplatin 74Magnetic Resonance Spectroscopy 71Biopsy 58Nivolumab 55Cisplatin 55Paclitaxel 46Cyclophosphamide 44durvalumab 37Radiotherapy 36Radiation 35Rituximab 34olaparib 33Etoposide 33Dexamethasone 33Ipilimumab 30Gemcitabine 30Lenalidomide 28Taxes 27Pemetrexed 27Doxorubicin 27Docetaxel 27Bevacizumab 24Prednisone 23Cytarabine 23X-Rays 22Trastuzumab 21cabozantinib 20Disulfides 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Has results × lazertinib × Clear all
NCT05663866 2026-06-02

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Janssen Research & Development, LLC

Phase 2 Active not recruiting
68 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-05-08

MARIPOSA

Janssen Research & Development, LLC

Phase 3 Active not recruiting
1,074 enrolled 13 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-05-08

MARIPOSA-2

Janssen Research & Development, LLC

Phase 3 Active not recruiting
776 enrolled 13 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05388669 2026-05-08

PALOMA-3

Janssen Research & Development, LLC

Phase 3 Active not recruiting
418 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡